Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis

Neurology

Volumn 50, Issue 4, 1998, Pages 1127-1133

  Mancardi, G L ^a   Sardanelli, F ^a   Parodi, R C ^a   Melani, E ^a   Capello, E ^a   Inglese, M ^a   Ferrari, A ^b   Sormani, M P ^b   Ottonello, C ^a   Levrero, F ^b   Uccelli, A ^a   Bruzzi, P ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; GLATIRAMER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOLOGIST;

EID: 0031900415     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.4.1127     Document Type: Article

References (26)

1. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766.
2. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16.
3. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480-489.
4. Stone LA, Smith ME, Albert PS, et al. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender and age. Neurology 1995;45:1122-1126.
5. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44:635-641.
6. van Walderveen MA, Barkhof F, Hommes OR, et al. Correlating MR imaging and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short TR/short TE ("T1-weighted") spin echo images. Neurology 1995;45:1684-1690.
7. Truyen L. Black holes: evolution and prognostic significance. Advances in MRI Contrast 1996;4:61-65.
8. The INFB Multiple sclerosis Study Group. Interferon beta 1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:665-661.
9. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276.
10. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
11. Paty DW, Li DKB, the UCB MS/MRI Study Group, the INFB Multiple Sclerosis Study Group. Interferon beta 1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
12. Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant human interferon beta la: a short-term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:251-258.
13. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast enhanced magnetic resonance imaging in relapsing remitting multiple sclerosis. Ann Neurol 1995;37:611-619.
14. Cohen JA, Grossman RI, Udupa JK, et al. Assessment of the efficacy of copolymer 1 in the treatment of multiple sclerosis by quantitative MRI. Neurology 1995;45(suppl 4):418. Abstract.
15. Miller DH, Barkhof F, Berry I, Kappos C, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-688.
16. Parodi RC, Sardanelli F, Rosso E, et al. Quantitative brain MR imaging of multiple sclerosis: a segmentation software using growing region. Eur Radiol 1997;7(suppl):S174. Abstract.
17. Parodi RC, Sardanelli F, Ferrari A, Sormani MP, Levrero F, Pilot A. Automatic identification of new lesions in brain MR longitudinal studies of multiple sclerosis. Eur Radiol 1997; 7(suppl):S192. Abstract.
18. Nauta JJP, Thompson AJ, Barkhof F, Miller DH. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel groups and crossover designs. J Neurol Sci 1994;122:6-14.
19. Mantel N. Chi-square test with one degree of freedom: extension of the Mantel-Haenszel procedure. J Am Stat Assoc 1963; 58:690-700.
20. Moreau T, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994;344:298-301.
21. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
22. Harris JO, Frank JA, Patronas N, et al. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early relapsing remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991;29:548-555.
23. Barkhof F. Role of MR imaging in the diagnosis of MS. Advances in MRI Contrast 1996;4:31-38.
24. Wolinsky JS. Copolymer 1: a most reasonable alternative therapy for early relapsing remitting multiple sclerosis with mild disability. Neurology 1995;45:1245-1247.
25. Arnon R, Sela M, Teitelbaum D. New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. J Neurol 1996; 243(suppl 1):S8-S13.
26. Katz D, Taubenberger JK, Canella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993;34:661-669.